** Shares of vaccine maker Moderna MRNA.O fall 2.7% to $27
** Moderna looking for partners to conduct late-stage studies on its experimental vaccines targeting Epstein-Barr virus, varicella zoster virus and genital herpes, the company said at an industry conference late on Wednesday
** MRNA said it will not take the experimental vaccines to late-stage trials on its own
** Including session's move, stock down 35% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.